Revance Therapeutics Inc (FRA:RTI)
€ 3.4 -0.1 (-2.86%) Market Cap: 371.12 Mil Enterprise Value: 655.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Q1 2020 Revance Therapeutics Inc Earnings Call Transcript

May 07, 2020 / 08:30PM GMT
Release Date Price: €17.2 (+4.88%)
Operator

Welcome to the Revance Therapeutics First Quarter 2020 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, May 7, 2020.

I would now like to turn the conference over to Jeanie Herbert, Senior Director of Investor Relations and Corporate Communications of Revance. Please go ahead, ma'am.

Jeanie D. Herbert
Revance Therapeutics, Inc. - Senior Director of IR & Corporate Communications

Thank you, Stacy. Joining us on the call today from Revance is President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Toby Schilke; Chief Operating Officer and President of R&D and Product Operations, Dr. Abhay Joshi; and Chief Commercial Officer of Aesthetics and Therapeutics, Dustin Sjuts.

Earlier today, Revance released financial results for the first quarter ended March 31, 2020. If you've not received this news release or you would like to be added to the company's distribution list to receive future releases, please go to the Investor Relations section of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot